Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update.

Martin MA, Hoffman JM, Freimuth RR, Klein TE, Dong BJ, Pirmohamed M, Hicks JK, Wilkinson MR, Haas DW, Kroetz DL, Clinical Pharmacogenetics Implementation Consortium
Clin Pharmacol Ther. 2014 95 (5): 499-500

PMID: 24561393 · PMCID: PMC3994233 · DOI:10.1038/clpt.2014.38

The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Abacavir Dosing were originally published in April 2012. We reviewed recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplementary Material online and included additional resources for applying CPIC guidelines to the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).

MeSH Terms (7)

Anti-HIV Agents Dideoxynucleosides Electronic Health Records Genotype HLA-B Antigens Humans Pharmacogenetics

Connections (1)

This publication is referenced by other Labnodes entities:

Links